Benchmark Reiterates Speculative Buy on HeartBeam, Maintains $8 Price Target
$BEAT
Medical/Dental Instruments
Health Care
Benchmark analyst Bill Sutherland reiterates HeartBeam (NASDAQ:BEAT) with a Speculative Buy and maintains $8 price target.
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/11/2025 | $8.00 | Speculative Buy → Buy | The Benchmark Company |
| 12/8/2025 | $2.50 | Buy | H.C. Wainwright |
| 10/31/2025 | $4.00 | Buy | Roth Capital |
| 12/20/2021 | $9.00 | Speculative Buy | Benchmark |
The Benchmark Company upgraded HeartBeam from Speculative Buy to Buy and set a new price target of $8.00
H.C. Wainwright initiated coverage of HeartBeam with a rating of Buy and set a new price target of $2.50
Roth Capital initiated coverage of HeartBeam with a rating of Buy and set a new price target of $4.00
4 - HeartBeam, Inc. (0001779372) (Issuer)
4 - HeartBeam, Inc. (0001779372) (Issuer)
4 - HeartBeam, Inc. (0001779372) (Issuer)
4 - HeartBeam, Inc. (0001779372) (Issuer)
4 - HeartBeam, Inc. (0001779372) (Issuer)
S-3 - HeartBeam, Inc. (0001779372) (Filer)
8-K - HeartBeam, Inc. (0001779372) (Filer)
10-Q - HeartBeam, Inc. (0001779372) (Filer)
HeartBeam's technology uniquely capable of assessing possible heart attacks outside of traditional clinical settings ALIGN-ACS study expected to complete patient enrollment quickly Milestone signifies key step toward future FDA indication expansion for heart attack assessment Future indication expansion would unlock large market with over 20 million patients at risk of a heart attack HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the first patients have been enrolled in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The first pati
HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, March 12, 2026 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2025, and will be providing updates on its key strategic growth initiatives, specifically the limited commercial launch and significant developments on the 12-lead ECG extended wear patch. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. They will
Marks HeartBeam's transition to commercial company Rapidly growing practice and highly engaged member population to enable broad adoption Enables efficient scaling of additional preventive cardiology and executive health programs Establishes initial foothold in structured direct pay healthcare segment representing 5 million patients HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced a commercial partnership with ClearCardio™, a leading preventive cardiology practice that has served thousands of patients through advanced heart health screening and personalized prevention programs. In
HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, March 12, 2026 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2025, and will be providing updates on its key strategic growth initiatives, specifically the limited commercial launch and significant developments on the 12-lead ECG extended wear patch. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. They will
Commercial Readiness Plans Accelerating in Anticipation of FDA 510(k) Clearance for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software for Arrhythmia Assessment Anticipated FDA Clearance in Q4 2025 is a Major Inflection Point as HeartBeam Evolves into a Commercial-Stage Company Focused on Growth Announced Partnership with HeartNexus to Provide On-Demand Cardiologist Reviews of Synthesized 12-Lead ECGs for Arrhythmia Assessment and Triage Patients Data Presented at AHA Scientific Sessions and HRX Live 2025 Continue to Advance HeartBeam's Pipeline for Ischemia Detection and Deep Learning Algorithms Management to Host Webcast and Conference Call Today at 4:30 p.m. E
HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, November 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2025, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed dur
Brings more than 25 years of experience in building and scaling groundbreaking cardiovascular technologies Will initially focus on launching the Company's FDA-cleared 12-lead ECG system for arrhythmia assessment Will lead the Company's broader commercialization strategy across key growth initiatives, including heart attack detection and the 12-lead ECG extended-wear patch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In this newly created role, Mr. Humbarger will lead commercial strate
Board expansion reflects Company's commitment to leadership and innovation in remote cardiac monitoring HeartBeam, Inc., (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the appointment of Chief Executive Officer, Robert Eno, to its Board of Directors. As the Company continues to make significant advancements towards commercial readiness, the Board elected to expand from eight to nine members to accommodate this addition. Mr. Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024. With over 30 years of experience in the medical technology industry, he has a proven
First cable-free, ambulatory ECG that captures the heart's electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics Patients can have the credit card-sized device with them at all times, ready to record an ECG whenever they feel symptoms and reduce delays in care Company to initiate Early Access Program to gain important patient and physician feedback on the use of the system in preparation for commercial launch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the US Food and Drug Administration (FDA) has granted 510(k) cl
SC 13D - HeartBeam, Inc. (0001779372) (Subject)
SC 13D - HeartBeam, Inc. (0001779372) (Subject)
SC 13D - HeartBeam, Inc. (0001779372) (Subject)